Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center